Free Trial
NASDAQ:XENE

Xenon Pharmaceuticals (XENE) Stock Price, News & Analysis

$38.98
-1.44 (-3.56%)
(As of 05/21/2024 ET)
Today's Range
$38.75
$40.66
50-Day Range
$39.50
$45.08
52-Week Range
$27.99
$50.99
Volume
359,807 shs
Average Volume
388,699 shs
Market Capitalization
$2.94 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.11

Xenon Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
51.6% Upside
$59.11 Price Target
Short Interest
Bearish
3.70% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.09mentions of Xenon Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$931,940 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.94) to ($3.38) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.02 out of 5 stars

Medical Sector

352nd out of 920 stocks

Pharmaceutical Preparations Industry

150th out of 413 stocks

XENE stock logo

About Xenon Pharmaceuticals Stock (NASDAQ:XENE)

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.

XENE Stock Price History

XENE Stock News Headlines

Xenon Pharmaceuticals: Q1 Earnings Snapshot
Xenon Pharmaceuticals Inc (XENE)
Xenon Pharmaceuticals Inc
XENE Apr 2024 47.500 put
See More Headlines
Receive XENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
5/21/2024
Next Earnings (Estimated)
8/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:XENE
Employees
251
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$59.11
High Stock Price Target
$65.00
Low Stock Price Target
$50.00
Potential Upside/Downside
+51.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-182,390,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$9.43 million
Book Value
$14.18 per share

Miscellaneous

Free Float
71,303,000
Market Cap
$2.94 billion
Optionable
Optionable
Beta
1.19
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Ian C. Mortimer C.M.A. (Age 48)
    CPA, M.B.A., President, CEO & Director
    Comp: $973.76k
  • Ms. Sherry Aulin (Age 40)
    Chief Financial Officer
    Comp: $3.03M
  • Ms. Andrea DiFabio J.D. (Age 56)
    Chief Legal Officer & Corporate Secretary
    Comp: $200.51k
  • Dr. Christopher E. Von Seggern M.B.A. (Age 45)
    M.P.H., M.P.H. M.B.A, Ph.D., Chief Commercial Officer
    Comp: $618.07k
  • Dr. Christopher John Kenney M.D.Dr. Christopher John Kenney M.D. (Age 53)
    Chief Medical Officer
    Comp: $684.22k
  • Ms. Shelley McCloskey B.A. (Age 64)
    Executive Vice President of Human Resources
  • Dr. Robin P. Sherrington Ph.D. (Age 63)
    Executive Vice President of Strategy & Innovation
    Comp: $351.67k
  • Dr. James R. Empfield Ph.D. (Age 63)
    Executive Vice President of Drug Discovery
    Comp: $323.43k
  • Ms. Sheila M. Grant M.B.A.
    M.Sc., MBA, Executive Vice President of R&D Operations

XENE Stock Analysis - Frequently Asked Questions

Should I buy or sell Xenon Pharmaceuticals stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XENE shares.
View XENE analyst ratings
or view top-rated stocks.

What is Xenon Pharmaceuticals' stock price target for 2024?

9 Wall Street analysts have issued 12-month price targets for Xenon Pharmaceuticals' shares. Their XENE share price targets range from $50.00 to $65.00. On average, they anticipate the company's stock price to reach $59.11 in the next year. This suggests a possible upside of 51.6% from the stock's current price.
View analysts price targets for XENE
or view top-rated stocks among Wall Street analysts.

How have XENE shares performed in 2024?

Xenon Pharmaceuticals' stock was trading at $46.06 at the start of the year. Since then, XENE stock has decreased by 15.4% and is now trading at $38.98.
View the best growth stocks for 2024 here
.

When is Xenon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our XENE earnings forecast
.

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) announced its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.07. The biopharmaceutical company had revenue of $1 million for the quarter. Xenon Pharmaceuticals's revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.63) earnings per share.

What other stocks do shareholders of Xenon Pharmaceuticals own?
Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Capital International Investors (3.28%), First Light Asset Management LLC (1.75%), Janus Henderson Group PLC (1.25%), Lord Abbett & CO. LLC (1.19%), Affinity Asset Advisors LLC (1.11%) and TimesSquare Capital Management LLC (0.98%). Insiders that own company stock include Christopher John Kenney, Dawn Svoronos, Frank A Holler, Gary Patou, Ian Mortimer, James R Empfield, Seggern Christopher Von, Sherrington Robin, Simon N Pimstone and Steven Gannon.
View institutional ownership trends
.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XENE) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners